XI'AN, CHINA--(Marketwire - September 14, 2010) - Skystar Bio-Pharmaceutical Company (
Mr. Weibing Lu, Skystar Bio-Pharmaceutical chairman and chief executive officer, commented on the occasion, "It is a great honor and pleasure to preside over today's closing bell ceremony. Our Company is the first ever U.S.-listed, China-based manufacturer and distributor of veterinary healthcare and medical products for the Chinese market. Skystar is in a growing industry in China, and feel that being listed as a NASDAQ Capital Markets exchange company is an important part of our long-term strategic plan to increase our brand visibility among customers and partners, and investors alike. On behalf of the management team, employees, and customers of Skystar, it is my hope to continue on this exemplary journey in building a world class business and to provide our shareholders a superior return in share value."
A live Webcast of the NASDAQ Closing Bell ceremony will be available today at 3:50 pm Eastern Time on the MarketSite section of NASDAQ's homepage at http://www.nasdaq.com/about/marketsitetowervideo.asx
To be added to the Company's email distribution for future news releases, please send your request to skystar@grayling.com.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 240 products. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
Contact Information:
Contacts:
Skystar Bio-Pharmaceutical Company
Scott Cramer
Director Corporate Development and U.S. Representative
(407) 645-4433
Investor Relations
Grayling
Christopher Chu
Director
(646) 284-9426
christopher.chu@grayling.com